An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic / Pharmacodynamic Profile of VX-970 as a Single Agent in Combination With Carboplatin in Subjects With Advanced Solid Tumours

Trial Profile

An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic / Pharmacodynamic Profile of VX-970 as a Single Agent in Combination With Carboplatin in Subjects With Advanced Solid Tumours

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Jun 2016

At a glance

  • Drugs M 6620 (Primary) ; Carboplatin
  • Indications Advanced breast cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions; Pharmacogenomic
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2016 Results (n=26) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 10 Jan 2016 According to Vertex media release, preliminary data expected at the medical meetings in 2016.
    • 09 Nov 2015 Interim results (n=25) presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top